Vaxxa AB (FRA:7WA0) Research & Development: €0.00 Mil (TTM As of Mar. 2026)


FRA:7WA0 Vaxxa AB FRA:7WA0
22 GF Score
Price €0.03
GF Value €0.05
! 2 Warning Signs
View Full Analysis

What is Vaxxa AB Research & Development?

Vaxxa AB FRA:7WA0 +0.65% 22 Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:7WA0 with a GF Score™ of 22/100 and a GF Value™ of €0.05. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vaxxa AB's Research & Development for the three months ended in Mar. 2026 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Vaxxa AB  (FRA:7WA0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vaxxa AB Research & Development Related Terms

Vaxxa AB Research & Development Historical Data

* Premium members only.

The historical data trend for Vaxxa AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxxa AB Research & Development Chart

Vaxxa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vaxxa AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:7WA0
22GF Score
Vaxxa AB FRA:7WA0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxxa AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Vaxxa AB (FRA:7WA0) has a Research & Development of €0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Vaxxa AB and its competitors.
Is Vaxxa AB's Research & Development too high?
Vaxxa AB's current Research & Development is €0.00 Mil. Overall, Vaxxa AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Vaxxa AB's Research & Development compare to CRM and SHOP?
Vaxxa AB's Research & Development of €0.00 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Software company?
A good Research & Development depends on the Software industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vaxxa AB and its competitors. Vaxxa AB's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxxa AB stock overvalued right now?
Vaxxa AB (FRA:7WA0) has a current Research & Development of €0.00 Mil. The stock's GF Value™ is €0.05, compared to a current price of €0.03 — trading 37.6% below its estimated fair value. The current Research & Development is €0.00 Mil. Vaxxa AB's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Vaxxa AB (FRA:7WA0), the current Research & Development is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vaxxa AB (FRA:7WA0) Overvalued in 2026?

Based on GuruFocus' analysis, Vaxxa AB stock appears to be undervalued. The current stock price of €0.03 is trading 37.6% below its estimated GF Value™ of €0.05.

Key valuation signals for FRA:7WA0:

  • Research & Development: €0.00 Mil
  • GF Value™: €0.05 vs. price of €0.03 (37.6% below fair value)
  • GF Score™: 22/100 with 2 warning signs

No single metric tells the full story. See the FRA:7WA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vaxxa AB Business Description

Other Exchanges VAXXA:Sweden
Address Maskinvagen 27, Norrbotten, Lulea, SWE, 972 54
Vaxxa AB is the auction site for those who want to buy and sell objects in vehicles, machinery, construction and industry. The company want to make it more accessible for both private individuals and companies to sell their objects with the motivation to pave the way for a more circular market. Vaxxa is Sweden's only auction platform where exactly the combination of auction broker and self-service is offered.
22GF Score

Get the complete analysis for FRA:7WA0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.05
GF Value